Axitinib vs. Cabozantinib in Metastatic Kidney Cancer
Clinical researchers did not find statistically significant differences in overall and progression-free survival between two approved second-line targeted agents—axitinib and cabozantinib—in sunitinib-refractory patients with metastatic renal cell carcinoma after correcting for baseline differences in patient-level data from the AXIS and METEOR trials. James Larkin, FRCP, PhD, of The Royal Marsden Hospital, London, presented these findings on behalf of his colleagues at the 2017 International Kidney Cancer Symposium.
More poor-risk patients were included in the AXIS study arm. So matching-adjusted indirect comparison (MAIC), a tool that corrects for imbalances in baseline characteristics, was used to adjust for imbalances between the two patient groups in the AXIS and METEOR trials. Results were not statistically different; median progression-free survival was 7.8 versus 9.1 months, and median overall survival was 23.8 months versus 21.4 months for axitinib and cabozantinib, respectively. Although cabozantinib treatment effects trended toward more positive outcomes, differences were not statistically significant.